In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Yervoy Approved in Europe, Bristol Activates Reimbursement Talks

This article was originally published in The Pink Sheet Daily

Executive Summary

BMS hopes that compelling survival data and unmet need will accelerate European patients' access to its novel advanced melanoma drug Yervoy.
Advertisement

Related Content

Bristol Tries Out New Selling Strategy With Yervoy Launch
Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label
Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label
NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis
UK's NICE Says No To Two CML Drugs; Invites Cost-Sharing Schemes

Topics

Advertisement
UsernamePublicRestriction

Register

PS072523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel